LadRx Corp - Company Profile

All the sales intelligence you need on LadRx Corp in one solution.

Save hours of research time with a comprehensive
Sales Intelligence Solution.
Understand how LadRx Corp fits into your total
addressable market and Ideal Customer Profile.
Gain competitive edge with triggers that tell you
when and how to engage with LadRx Corp.

LadRx Corp: Premium Databases

Contact the team or request a demo to find out how our data can drive your business forward

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Headline	Published	Journalists
Showing 3 of 13+ results.
Deserunt mollit sunt Lorem laborum do id aliqua dolore	13 Oct 2016	Lorem
CytRx’s Phase IIb trial of aldoxorubicin in small-cell lung cancer to complete enrolment by October – source	15 Aug 2016	Hamish McDougall
Eli Lilly’s olaratumab an attractive STS option, sparks discussion about combinations beyond doxorubicin – experts	05 Jul 2016	Alaric DeArment
CytRx’s aldoxorubicin glioblastoma responses potentially encouraging, but drug mostly leaves experts underwhelmed	08 Jun 2016	Alaric DeArment

Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.

Drug Insights:

Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
Material intelligence on competitors, including breaking news
Insight on companies’ business development needs and strategies

Outsourcing Insights:

Insight on companies’ CRO and business development needs, strategies and relationships

Remove risk and uncertainty

Gain a competitive edge

Secure actionable leads

Gain a 360-degree view of LadRx Corp and make more informed decisions for your business

Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer